Natera, INC Form 4 insider transactions

Natera's Chief Financial Officer, Michael Burkes Brophy, vested 59,596 shares of common stock on January 14, 2026, as part of a pre-planned performance-based Restricted Stock Unit award.

Natera Inc.'s CEO and President, Steven Leonard Chapman, acquired 152,718 shares of common stock through the vesting of performance-based Restricted Stock Units.

Natera's President and Chief Business Officer, John Fesko, vested 44,698 shares of common stock on January 14, 2026, following the certification of a performance milestone.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, vested 44,698 shares of common stock on January 14, 2026, following the certification of a performance milestone.

Natera's SEC and Chief Legal Officer, Daniel Rabinowitz, acquired 37,248 shares of common stock through the vesting of a performance-based Restricted Stock Unit award.

Natera Co-Founder and Director Jonathan Sheena acquired 7,450 shares of common stock through the vesting of a performance-based Restricted Stock Unit award.

Natera Co-Founder Jonathan Sheena exercised options to acquire 39,615 shares of common stock at $9.59 per share.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 2,951 shares of common stock for approximately $675,800 under a pre-arranged 10b5-1 trading plan.

Natera Inc. CEO and President Steven Leonard Chapman sold 3,848 shares of common stock on January 2, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Natera Co-Founder Jonathan Sheena sold 1,500 shares of common stock through pre-arranged trading plans on December 19, 2025.

Jonathan Sheena, Co-Founder and Director of Natera, Inc., reported the disposition of 4,130 shares of common stock, including a charitable contribution and sales under a pre-arranged trading plan.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, reported exercising stock options, selling shares to cover taxes, and making charitable contributions of common stock.

Natera Director Herm Rosenman sold approximately $11 million worth of common stock in multiple transactions on December 12, 2025, following the acquisition of 132 restricted stock units on October 31, 2025.

Jonathan Sheena, Co-Founder and Director of Natera, Inc., exercised stock options to acquire 4,436 shares of common stock.

Natera Inc. Director Rowan E. Chapman exercised stock options and subsequently sold a portion of the acquired common stock.

Natera's SEC and Chief Legal Officer, Daniel Rabinowitz, exercised stock options for 6,902 shares of common stock at $19.68 per share.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 2,900 shares of common stock on December 1, 2025, under a pre-arranged 10b5-1 trading plan.

Natera Inc.'s CEO and President, Steven Leonard Chapman, sold 4,400 shares of common stock on December 1, 2025, through a pre-arranged 10b5-1 trading plan.

A director at Natera, Inc. executed pre-planned sales of 75,000 common shares totaling approximately $17.5 million through estate planning vehicles.

Natera Co-Founder and Director Jonathan Sheena sold 14,000 shares of Natera common stock for approximately $3.2 million through pre-arranged Rule 10b5-1 trading plans.

Natera Director Roy D. Baynes executed multiple stock option exercises and subsequent sales of common stock, reducing his direct beneficial ownership by 5,112 shares.

Natera, Inc. Co-Founder and Director Jonathan Sheena reported sales of 4,960 shares of common stock through pre-arranged Rule 10b5-1 trading plans.

Natera's Executive Chairman, Matthew Rabinowitz, sold 22,900 shares of common stock on November 4, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Natera Co-Founder Jonathan Sheena sold 4,000 shares of common stock for approximately $800,273.60 through a pre-arranged 10b5-1 trading plan.

Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold 3,000 shares of common stock for approximately $596,000 under a pre-arranged 10b5-1 trading plan.

Natera Director Brinkley Ruth Williams received 97 fully vested Restricted Stock Units as quarterly board compensation.

Natera Director Gail Marcus reported the acquisition of 121 shares as compensation and the subsequent sale of 122 shares under a pre-arranged trading plan.

Natera, Inc. Director Rowan E Chapman acquired 128 shares of common stock through a fully vested RSU grant on October 31, 2025, in lieu of quarterly retainer fees.

Natera Director Roelof Botha received 149 shares of common stock as compensation for board service, increasing his direct beneficial ownership in the company.

Natera, Inc. Director Monica Bertagnolli acquired 93 fully vested Restricted Stock Units in lieu of quarterly retainer fees for board service.